Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab‐Mediated Cytokine Elevations on Cytochrome P450 Enzyme Activity
Author:
Affiliation:
1. Amgen, Clinical PharmacologyModeling and Simulation Group, Department of Medical SciencesThousand Oaks California USA
2. Amgen Research (Munich)Munich Germany
Publisher
Wiley
Subject
Pharmacology (medical),Modeling and Simulation
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12003
Reference39 articles.
1. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
2. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
3. Gore L.et al. Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL). American Society of Clinical Oncology Annual Meeting; May 31–June 4; Chicago IL;2013.
4. Blinatumomab exposure and pharmacodynamic response in patients with non‐Hodgkin lymphoma (NHL);Hijazi Y.;J. Clin. Oncol,2013
5. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review;European Journal of Cancer;2024-07
2. Is PBPK useful to inform product label on managing clinically significant drug interactions mediated by cytokine release syndrome?;CPT: Pharmacometrics & Systems Pharmacology;2024-06-12
3. Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab;CPT: Pharmacometrics & Systems Pharmacology;2024-06-03
4. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab;CPT: Pharmacometrics & Systems Pharmacology;2023-12-14
5. Assessment of CYP3A‐mediated drug interaction via cytokine (IL‐6) elevation for mosunetuzumab using physiologically‐based pharmacokinetic modeling;CPT: Pharmacometrics & Systems Pharmacology;2023-12-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3